apomorphine has been researched along with sch 23982 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (50.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Adams, EF; Fahlbusch, R; Nomikos, P; Reif, M; Schrell, UM | 1 |
Ackerman, M; Artman, LD; Asin, KE; Bednarz, L; Johnson, MC; Kebabian, JW; Kerkman, DJ; MacKenzie, RG; Montana, W; Stampfli, H | 1 |
2 other study(ies) available for apomorphine and sch 23982
Article | Year |
---|---|
Growth of cultured human cerebral meningiomas is inhibited by dopaminergic agents. Presence of high affinity dopamine-D1 receptors.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Apomorphine; Benzazepines; Binding, Competitive; Bromocriptine; Butaclamol; Cell Division; Dopamine; Dopamine Agents; Humans; Meningioma; Receptors, Dopamine; Receptors, Dopamine D1; Tumor Cells, Cultured | 1990 |
A-69024: a non-benzazepine antagonist with selectivity for the dopamine D-1 receptor.
Topics: Adenylyl Cyclases; Animals; Apomorphine; Benzazepines; Binding, Competitive; Catalepsy; Dihydroxyphenylalanine; Haloperidol; Injections, Subcutaneous; Iodine Radioisotopes; Male; Motor Activity; Papaverine; Prolactin; Rats; Rats, Inbred Strains; Receptors, Dopamine; Stereotyped Behavior; Tetrahydroisoquinolines | 1989 |